GSK on Tuesday said it will pay $2 billion to acquire Bellus Health, a Canada-based developer of an experimental drug for chronic cough that’s in late-stage clinical trials. Deal terms value each Bellus share at $14.75, roughly double their closing price on Monday. The companies expect the acquisition will close in the third quarter, and Bellus’ board has unanimously voted in its favor. Bellus’ drug, called camlipixant, is currently being tested in two Phase 3 studies of people with persistent cough that either doesn’t have a clear cause or can’t be relieved by treatment for an underlying condition. Results are expected in late 2024 and in 2025, respectively. With the Bellus deal, GSK will gain a drug that could compete with a similar treatment being developed by Merck & Co. Both medicines are designed to work by targeting a receptor known as P2X3, and could become the first ...
Novartis UK and digital health company Cievert have announced a digital innovation partnership to help streamline the management of rheumatological and dermatological diseases. The initiative aims to support patient care in rheumatology and dermatology by utilising patient-reported data and allowing clinicians to prioritise appointments on a needs-based model of care. The partnership, which was identified via the Novartis BIOME selection procedure, will see Novartis and Cievert work closely with the NHS to launch pilot programmes across the UK. The digital platform will aim to collaborate with patients, healthcare professionals (HCPs) and the NHS across the UK and support them in three areas. Firstly, the partnership will aim to capture patient digital health records in one platform to reduce misalignment among healthcare teams. Secondly, the programme will aim to coordinate and prioritise appointments based on patient need, rather than routinely scheduled reviews. Lastly, the initiative will collect real-time patient data in ...
AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) hit the primary endpoint in a Phase III study in chronic lymphocytic leukaemia (CLL). In the ELEVATE-RR trial, Calquence demonstrated non-inferior progression-free survival (PFS) compared to Janssen’s BTK inhibitor Imbruvica (ibrutinib) in adult patients with previously-treated, high risk CLL – the primary endpoint of the study. AZ’s drug also met a key secondary endpoint for safety, with Calquence-treated patients demonstrating a statistically significant lower incidence of atrial fibrillation compared to patients treated with Imbruvica. In a statement, AZ added that there was also a ‘descriptive’ trend for numerically favourable overall survival for Calquence. “With over forty months of follow-up, today’s results confirm that Calquence, a selective BTK inhibitor, displays superior safety in atrial fibrillation without compromising efficacy,” said José Baselga, executive vice president, Oncology R&D at AZ/ “The totality of the data confirm our confidence in the favourable benefit-risk profile of Calquence,” ...
Nearly millions of people throughout the world are living with chronic pain in one form or the other. With the rise of opioids in the epidemic level, there arises a rise in search for new treatment measures. The wearables company named NeuroMetrix had redesigned their device named Quell for an easier and convenient utilization. The modified Quell 2.0 app has taken the FDA approved nerve stimulation technology to the next level, which is supposed to be the latest breakthrough for chronic pain treatment. The Quell 2.0 device is smarter, 50% smaller and 20% more powerful. The new Quell 2.0 app is available online at www.QuellRelief.com. Quell 2.0 app is integrated with a neurostimulation microchip which includes all the features of Quell device. It easily adapts to changes in body position and automatically starts the therapy in switch-on mode. This app is user-friendly with a varied automation feature like start and stop, ...
Availability of a medical professional 24x7 to monitor a patient suffering from diabetes and cardiac conditions is impossible outside a hospital setting. This is where remote monitoring comes to the rescue. Patients suffering from chronic illnesses such as these want regular medical attention and hence, the demand for remote health monitoring systems is on the rise.
Findings from two international, randomized, double-blind, phase III, placebo-controlled trials published in the September issue of Gastroenterology revealed that the oral second-generation thrombopoietin agonist avatrombopag (Doptelet) when given once a day, notably decreased the requirement for platelet transfusion...
The University of Manchester and Salford Royal NHS Trust researchers have built a lamp to treat chronic ulcers.
A research team from Italy reported that a glance of light might provide relief from pain. They first identified the oversensitive nerve cells that cause chronic pain. Then, a light-sensitive chemical was developed and injected, which binds to these nerve cells. Next, a flash of near-infrared light was passed to the exact nerve in order to provide instant pain relief. This strategy was experimentally proved in mice.
The American Heart Association, one of the leading non-profit organizations that foster cardiac care, is working to enhance community health through a new business line - Health Screening Services (HSS). The new health screening services will help consumers become more conscious of personal health risk factors and motivate them to make changes in their behaviors and lifestyle.
The AMA and Google are joining forces on an mHealth challenge designed to improve care coordination for people with chronic conditions through mobile health platforms linking the patient with the doctor.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.